Dr Reddy's down nearly 4%; mcap dips by Rs 1,887 cr post Q3

Image
Press Trust of India Mumbai
Last Updated : Feb 09 2016 | 5:48 PM IST
Shares of Dr Reddy's Laboratories today fell by nearly 4 per cent after the company's December quarter earnings failed to meet market expectations.
The stock went down by 3.61 per cent to settle at Rs 2,959.65 on BSE. During the day, it lost 3.92 per cent to Rs 2,950.
On NSE, shares of the company dropped by 3.6 per cent to end at Rs 2,959.60.
The company's market valuation diminished by Rs 1,887.11 crore to Rs 50,493.89 crore.
"Dr Reddys Lab posted results below expectations both on top and bottom-line," said Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking.
Dr Reddy's Laboratories today posted a marginal increase in consolidated net profit at Rs 579.2 crore for the third quarter ended December 31, hit by weak sales in emerging markets like Russia, CIS nations and Romania.
The company had posted a net profit of Rs 574.5 crore during the same period of previous fiscal.
Net income from sales and services rose to Rs 3,967.9 crore for the third quarter as compared to Rs 3,843.1 crore during the same period of previous fiscal, Dr Reddy's Laboratories said in a regulatory filing.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 09 2016 | 5:48 PM IST

Next Story